SIGLANDA

US serial number:85021702
Application filling date:Apr. 23, 2010
Register:Principal
Mark type:Trademark
Status:Registered. The registration date is used to determine when post-registration maintenance documents are due.
Status date:Jan. 07, 2014
Publication date:Oct. 12, 2010
Standard character claim:Yes. The mark consists of standard characters without claim to any particular font style, size, or color.
Mark drawing type:4 - STANDARD CHARACTER MARK
Foreign priority claimed:Yes
Foreign foreign application number:2542363
Foreign foreign application filling date:Mar. 18, 2010
Foreign foreign registration number:2542363
Foreign foreign registration date:Mar. 18, 2010
Foreign foreign application registration country:UNITED KINGDOM
Foreign foreign expiration date:Mar. 18, 2020
Goods and services:For: Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabo
Current owner owner name:Glaxo Group Limited
Current owner owner address:980 Great West Road Brentford, Middlesex UNITED KINGDOM TW89GS
Current owner legal entity type:CORPORATION
Current owner state or country:UNITED KINGDOM
Attorney name:Christopher M. Hanes
Attorney email:trademarks@gsk.com
Attorney docket number:PRJ/7056097/
Attorney email authorized:Yes
Correspondent name address:Christopher M. Hanes GlaxoSmithKline Five Moore Drive Legal Global Trademarks, Mailstop: 5.5A Research Triangle Park, NORTH CAROLINA UNITED STATES 27709-0183
Correspondent phone:919.483.2723
Correspondent email:trademarks@gsk.com
Correspondent fax:919.315.3023
Correspondent email authorized:Yes
Domestic representative name:Christopher M. Hanes
Domestic representative phone:919.483.2723
Domestic representative fax:919.315.3023
Domestic representative email:trademarks@gsk.com
Domestic representative email authorized SIGLANDA:Yes

Reviews

Required fields are marked *